Literature DB >> 31296645

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes.

Devin Abrahami1,2, Antonios Douros1,3,4, Hui Yin1, Oriana H Y Yu1,5, Laurent Azoulay6,2,7.   

Abstract

Entities:  

Year:  2019        PMID： 31296645     DOI： 10.2337/dc19-0849

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  8 in total

1.  Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.

Authors:  Andrea Cowan; Nivethika Jeyakumar; Yuguang Kang; Stephanie N Dixon; Amit X Garg; Kyla Naylor; Matthew A Weir; Kristin K Clemens
Journal:  Clin J Am Soc Nephrol       Date:  2022-05-26       Impact factor: 10.614

Review 2.  Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences.

Authors:  Jessica A Dominguez Rieg; Jianxiang Xue; Timo Rieg
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-09       Impact factor: 2.894

3.  Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.

Authors:  Elisabetta Patorno; Ajinkya Pawar; Deborah J Wexler; Robert J Glynn; Lily G Bessette; Julie M Paik; Mehdi Najafzadeh; Kimberly G Brodovicz; Anouk Déruaz-Luyet; Sebastian Schneeweiss
Journal:  Diabetes Obes Metab       Date:  2021-12-01       Impact factor: 6.577

Review 4.  Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.

Authors:  Thomas M Caparrotta; Andrew M Greenhalgh; Karen Osinski; Robert M Gifford; Svenja Moser; Sarah H Wild; Rebecca M Reynolds; David J Webb; Helen M Colhoun
Journal:  Diabetes Ther       Date:  2021-03-04       Impact factor: 2.945

5.  Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.

Authors:  Kyoung Hwa Ha; Dae Jung Kim; Yong Jun Choi
Journal:  J Diabetes Investig       Date:  2022-03-04       Impact factor: 3.681

6.  Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study.

Authors:  Samantha T Harris; Elisabetta Patorno; Min Zhuo; Seoyoung C Kim; Julie M Paik
Journal:  Diabetes Care       Date:  2021-08-03       Impact factor: 17.152

7.  Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.

Authors:  Salva R Yurista; Herman H W Silljé; Harry van Goor; Jan-Luuk Hillebrands; Hiddo J L Heerspink; Luiz de Menezes Montenegro; Silke U Oberdorf-Maass; Rudolf A de Boer; B Daan Westenbrink
Journal:  Cardiovasc Drugs Ther       Date:  2020-06       Impact factor: 3.947

Review 8.  The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.

Authors:  Emily Brown; John P H Wilding; Uazman Alam; Thomas M Barber; Janaka Karalliedde; Daniel J Cuthbertson
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.